Inotiv (NASDAQ:NOTV) Issues Earnings Results

Inotiv (NASDAQ:NOTV) released its quarterly earnings data on Wednesday. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative net margin of 22.10% and a negative return on equity of 15.86%.

Inotiv Stock Down 3.4 %

NOTV stock traded down $0.14 during midday trading on Friday, reaching $3.79. 199,848 shares of the company’s stock traded hands, compared to its average volume of 647,940. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 2.29. The firm’s fifty day moving average price is $4.43 and its 200-day moving average price is $2.80. Inotiv has a 52 week low of $1.23 and a 52 week high of $11.42. The company has a market cap of $98.45 million, a price-to-earnings ratio of -0.90 and a beta of 3.58.

Insider Buying and Selling at Inotiv

In related news, COO John Gregory Beattie acquired 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $142,500.00. Following the purchase, the chief operating officer now owns 161,761 shares in the company, valued at approximately $768,364.75. The trade was a 22.77 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nigel Brown bought 7,500 shares of Inotiv stock in a transaction dated Tuesday, December 10th. The stock was purchased at an average price of $4.26 per share, with a total value of $31,950.00. Following the purchase, the director now owns 65,537 shares in the company, valued at approximately $279,187.62. This represents a 12.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 71,029 shares of company stock valued at $314,248 and have sold 26,872 shares valued at $112,854. Insiders own 7.80% of the company’s stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.